

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 28 January 2023.

I am pleased to confirm the following.

Patients with acute myeloid leukaemia (AML)

1. How many patients have received treatment with venetoclax for AML during the past 24 months? Note: please provide data for the most recent 24-month period available via your prescribing/management system.

Answer: 30

2. What is the average daily dose (mg) for AML patients receiving venetoclax during the past 24 months?

Answer: This information is not recorded.

3. What is the average cycle intensity (days) for AML patients receiving venetoclax during the past 24 months? (e.g., 14-day cycles, 21-day cycles, other length of cycle)

Answer: 14 Days

4. What is the average duration of treatment (months) for AML patients receiving venetoclax during the past 24 months?

Answer: 2 to 3 cycles

Patients with chronic lymphocytic leukaemia (CLL)

Please complete the table below based on the number of patients that have received venetoclax in each of the specified regimens for CLL in the last 24 months.

Note: please provide data for the most recent 24-month period available via your prescribing/management system.

	Treatment regimens		
	Venetoclax + obinutuzumab	Venetoclax + rituximab	Venetoclax monotherapy
Total number of CLL patients receiving this treatment regimen during the past 24 months	5		
Average daily maintenance dose (mg) of venetoclax for patients initiated on this regimen during the past 24 months*	This information is not recorded.		
Average duration (months) of venetoclax treatment for patients initiated on this regimen during the past 24 months	5		

*We would like to understand the average daily dose of venetoclax in CLL patients during maintenance treatment i.e. after the initial 8-week period during which patients would be receiving a titration regimen.

Patients with acute myeloid leukaemia (AML) or chronic lymphocytic leukaemia (CLL)

6. Please complete the table below with the average number of venetoclax 10 mg x 14 tablet packs† used per AML or CLL patient receiving each of the specified regimens during the past 24 months.

	AML treatment regimen	CLL treatment regimens		
	Venetoclax + azacitidine	Venetoclax + obinutuzumab	Venetoclax + rituximab	Venetoclax monotherapy
Average number of venetoclax 10 mg x 14 tablet packs used per patient in each treatment regimen during the past 24 months	4	1	0	5

†Note: There are five different pack sizes of venetoclax available in the UK:

- Pack 1: venetoclax 10 mg x 14 tablets
- Pack 2: venetoclax 50 mg x 7 tablets
- Pack 3: venetoclax 100 mg x 7 tablets
- Pack 4: venetoclax 100 mg x 14 tablets
- Pack 5: venetoclax 100 mg x 112 tablets

7. Please can you share your prescribing protocol(s) for venetoclax in AML and CLL?

Answer: [NSSG - Haematology \(oxford-haematology.org.uk\)](http://nssg-oxford-haematology.org.uk)

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.
